AnaptysBio, Inc. (ANAB) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-03

Business type: Asset play

How it makes money

It earns revenue through milestone payments and royalties from partner-commercialized antibodies and license fees from collaboration agreements.

It operates as a clinical-stage biotechnology company that generates income primarily through financial collaborations with major pharmaceutical partners. Specifically, it recognizes revenue from milestones and royalties achieved under its immuno-oncology collaboration with GSK regarding Jemperli, alongside license and transition services revenue from its collaboration with Vanda Pharmaceuticals Inc. regarding imsidolimab.

Because its proprietary internal pipeline remains in clinical development without commercialized products, these external partnerships provide the sole source of incoming revenue while the internal pipeline advances through clinical trials.

What protects it: the moat

It attempts to protect its market position through patent rights covering its proprietary antibodies and therapeutic pipeline.

Management asserts that obtaining and protecting intellectual property rights in the United States and globally is essential for maintaining a competitive advantage against rival therapeutics. Without enforceable patent protection, competitors could more easily develop and market similar biological products that undercut its commercial opportunities.

However, the filing highlights that securing and defending these intellectual property rights involves substantial uncertainty, meaning management's stated advantage depends entirely on successful legal execution and patent prosecution.

What growth costs

It must continuously reinvest capital into research, clinical trials, and pipeline development to advance its unapproved drug candidates.

The filing does not disclose specific aggregate ongoing monetary figures for research and development expenditures or maintenance capital requirements. However, it explicitly states that advancing pipeline candidates like rosnilimab, ANB033, and ANB101 requires substantial funding for clinical trials, manufacturing, and operational overhead.

Furthermore, management notes that the proposed separation of the business into two independent publicly traded companies will require adequate capital to fund operations for at least 12 months following completion.

What could damage it

If its primary partnership with GSK underperforms or terminates, its incoming collaboration revenue and financial stability would suffer permanent impairment.

The company relies heavily on ongoing milestone and royalty payments derived from its immuno-oncology collaboration with GSK for Jemperli. If GSK encounters commercial difficulties, prioritizes competing therapies, or terminates the collaboration agreement, the company would lose its primary active revenue stream. This loss would severely impair its financial condition and restrict its ability to independently fund clinical development programs.

About AnaptysBio, Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Other companies in Biotechnology